Investigation of anti-SARS-CoV-2 multimeric bicyclic peptide inhibitors in a range of preclinical therapeutic settings

The spread of respiratory viruses, such as influenza and SARS-CoV-2, has presented significant challenges over the last 30 years, with few effective therapeutic options available to this day. Bicyclic peptides represent a unique, modular modality in the antiviral armamentarium against future pandemics. This study utilizes tool molecules to provide a deeper evaluation of multivalent bicyclic (Bicycle) molecule efficacy in several preclinical SARS-CoV-2 challenge settings. We explore both pre-exposure prophylaxis and post-exposure therapeutic settings via subcutaneous and intranasal routes of administration. We contextualize this further in bespoke scenarios where the immune system is compromised, as well as viral transmission. Promisingly, in all studies, we observe efficacy, significantly reducing infectious viral burden at each study endpoint. These data further support the candidacy of Bicycle molecules as a differentiated antiviral therapeutic class in the context of pandemic preparedness. IMPORTANCE: The COVID-19 pandemic triggered a rapid wave of innovation, accelerating the delivery of new vaccine technology and antiviral treatments. In our first paper, we described the discovery and molecular optimization of Bicycle molecules as a novel drug class for the potential treatment of SARS-CoV-2. Here, we have performed deeper characterization of these tool molecules in established animal models to evaluate scenarios for deployment, simulating SARS-CoV-2 transmission, testing more convenient delivery routes, such as intranasal, as well as looking at immunocompromised animals. The Bicycle molecules demonstrated positive outcomes in each of these studies and suggest that Bicycle molecules, as convenient and effective antiviral treatments, could be an important addition to help future preparedness against new viral pandemics.

Authors

Institutions

Publication Details

Journal
Journal of Virology
Published
2026-11-18
DOI
https://doi.org/10.1128/jvi.01224-26
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Investigation of anti-SARS-CoV-2 multimeric bicyclic peptide inhibitors in a range of preclinical therapeutic settings

Katherine U. Gaynor, Phil Jeffrey, Joanne Sharp, Michael J. Skynner et al.
3 links
Journal of Virology
SARS-CoV-2 and COVID-19 Research
article

Investigation of anti-SARS-CoV-2 multimeric bicyclic peptide inhibitors in a range of preclinical therapeutic settings

Katherine U. Gaynor, Phil Jeffrey, Joanne Sharp, Michael J. Skynner, Ieva Drulyte, Adam Kirby, Simone Pellegrino, Maximilian A. J. Harman, James P. Stewart, Eduardo Gallardo‐Toledo, Edyta Kijak, Steven J. Stanway, Brian McGuinness, G.A. Bezerra, Liuhong Chen, Guido Papa, Lee M. Tatham, Joanne Herriott, Andrew Owen, Eleanor G. Bentley, Paul Beswick, Katerine Van Rietschoten, Parul Sharma
article en

Abstract

The spread of respiratory viruses, such as influenza and SARS-CoV-2, has presented significant challenges over the last 30 years, with few effective therapeutic options available to this day. Bicyclic peptides represent a unique, modular modality in the antiviral armamentarium against future pandemics. This study utilizes tool molecules to provide a deeper evaluation of multivalent bicyclic (Bicycle) molecule efficacy in several preclinical SARS-CoV-2 challenge settings. We explore both pre-exposure prophylaxis and post-exposure therapeutic settings via subcutaneous and intranasal routes of administration. We contextualize this further in bespoke scenarios where the immune system is compromised, as well as viral transmission. Promisingly, in all studies, we observe efficacy, significantly reducing infectious viral burden at each study endpoint. These data further support the candidacy of Bicycle molecules as a differentiated antiviral therapeutic class in the context of pandemic preparedness. IMPORTANCE: The COVID-19 pandemic triggered a rapid wave of innovation, accelerating the delivery of new vaccine technology and antiviral treatments. In our first paper, we described the discovery and molecular optimization of Bicycle molecules as a novel drug class for the potential treatment of SARS-CoV-2. Here, we have performed deeper characterization of these tool molecules in established animal models to evaluate scenarios for deployment, simulating SARS-CoV-2 transmission, testing more convenient delivery routes, such as intranasal, as well as looking at immunocompromised animals. The Bicycle molecules demonstrated positive outcomes in each of these studies and suggest that Bicycle molecules, as convenient and effective antiviral treatments, could be an important addition to help future preparedness against new viral pandemics.

Journal of Virology
University of Liverpool (GB), MRC Laboratory of Molecular Biology (GB), Thermo Fisher Scientific (Netherlands) (NL), Bicycle Therapeutics (United Kingdom) (GB), Centre of Excellence for Long-acting Therapeutics (GB)
Wellcome Trust, Innovate UK
Good health and well-being
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon